 FDA designation will facilitate development and expedited review of companys lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis GM1, PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease FDA designation will facilitate development and expedited review of companys lead gene therapy product candidates for life-threatening diseases with unmet medical needs: PBGM01 for GM1 gangliosidosis GM1, PBFT02 for frontotemporal dementia with granulin mutations, and PBKR03 for Krabbe disease 